Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viroblock SA

This article was originally published in Start Up

Executive Summary

Viroblock SA is taking a decidedly pragmatic approach to commercializing a solution of two ingredients "generally recognized as safe" that when combined appear to inactivate viruses. The company is looking to leverage a liquid mixture that contains liposomes and cyclodextrin, a chemical frequently harnessed for its ability to bond with hydrophobic substances to fight viral infections.

You may also be interested in...



Start-Up Previews (11/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.

Start-Ups Look For Places In Future HCV Combo Regimens

With more than 50 drugs in development for hepatitis C, what comes next after first-generation protease inhibitors and what opportunity might there be for small start-up firms in a space where so many Big Pharma and specialty pharma companies are active? Approvals of direct-acting antiviral therapies are just around the corner in hepatitis C, and smaller companies are looking to provide parts of the puzzle in next-generation drug cocktails that will tackle the growing disease. However, in order for small companies to succeed in this highly competitive space they'll need highly differentiated products. START-UP profiles AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus.

Start-Up Previews (11/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.

Topics

Related Companies

UsernamePublicRestriction

Register

GB140458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel